Multicenter, open label, prospective, post approval for restricted use under emergency situation study to evaluate the safety and efficacy of Favipiravir 200mg and 800 mg for treatment of adult Indian patients with mild to moderate COVID-19 disease.

Mylan Laboratories Limited0 个研究点目标入组 196 人开始时间: 待定最近更新: 2024年4月29日

试验速览

阶段: 4 期
状态: 已完成
发起方: Mylan Laboratories Limited
入组人数: 196

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

入选标准

•1. Adults with confirmed COVID 19 infection.
•2. Subject (or legally authorized representative) provides informed consent prior to initiation of any study procedures.
•3. Subject (or legally authorized representative) understands and agrees to comply with planned study procedures.
•4. Male or non-pregnant female adult 18 to 65 years of age at time of enrollment.
•5. Duration of symptoms less than 7 days.
•6. Screening ECG without clinically significant ECG abnormalities.
•7. Has laboratory confirmed SARS CoV 2 infection as determined by polymerase chain reaction (PCR) or other commercial or public health assay in any specimen, as documented by either or the following:
•i) PCR positive in sample collected less than 72 hours prior to Day 1; OR
•ii) PCR positive in sample collected more than or equal to 72 hours prior to Day 1, documented inability to obtain a repeat sample (e.g. due to lack of testing supplies, limited testing capacity, results taking more than 24 hours, etc.) AND progressive disease suggestive of ongoing SARS CoV 2 infection. OR
•iii) Positive COVID-19 Antigen Test.
•8. Illness of mild or moderate severity as defined below:
•i) Patients with uncomplicated upper respiratory tract infection, may have mild symptoms such as fever, cough, sore throat, nasal congestion, malaise, headache. AND
•ii) Without evidence of breathlessness (RR less than 24) or Hypoxia (Normal saturation SpO2 greater than 94 percent).
•9. Moderate:
•i) Pneumonia with no signs of severe disease.
•ii) Presence of clinical features of dyspnea and or hypoxia, fever, cough, including SpO2 in range 90 to 94 percent on room air and Respiratory Rate more or equal to 24 per minute.
•10. Women of childbearing potential must agree to either abstinence or use at least one primary form of contraception not including hormonal contraception from the time of screening through Day 28. Agrees to not participate in another clinical trial for the treatment of COVID 19 or SARS CoV 2 through Day 28.

排除标准

•1. Patients with clinical signs of pneumonia plus one of the following: respiratory rate more than 30 breaths per min, severe respiratory distress, SpO2.
•2. Requiring mechanical ventilation or ECMO at screening.
•3. Estimated glomerular filtration rate (eGFR) less than 30 ml per min (including patients receiving hemodialysis or hemofiltration).
•4. Pregnancy or breast feeding.
•5. Evidence of multiorgan failure.
•6. Allergy to any study medication.
•7. Patients on medicinal products which are contraindicated to be used with any study medication.
•8. Any malignancy or cerebro vascular complications.
•9. Any other condition as per the physician’s discretion which would make the patient unsuitable for enrollment in the study.
•10. Participated in any other clinical trial or taken investigational drug within 1 month.
•11. Refractory nausea, vomiting, or chronic gastrointestinal disorders, inability to swallow the study drug or having undergone extensive bowel resection which may affect adequate absorption of Favipiravir.
•12. AST/ALT more than 5.0 ULN or bilirubin more than 3.0 ULN.
•13. Serum Uric Acid greater than 3.0 ULN or having symptoms of and being treated for active gout.

研究者

发起方

Mylan Laboratories Limited

相似试验

尚未招募

不适用

A Study to Assess the Safety and Efficacy of Remdesivir in COVID-19 infected Indian patients

CTRI/2021/12/039011Jubilant Generics Limited

进行中（未招募）

不适用

EUCTR2006-004679-36-FRaboratoire HRA Pharma22

进行中（未招募）

不适用

Prospective, open-label, multicenter, international study of mifepristone for symptomatic treatment of Cushing s syndrome caused by ectopic Adrenal Corticotrophin Hormone ACTH secretion - HRA052015 in EAS

EUCTR2006-004679-36-ITABORATOIRE HRA PHARMA22

进行中（未招募）

不适用

EUCTR2006-004679-36-NLaboratoire HRA Pharma22

进行中（未招募）

不适用

Prospective, open-label, multicenter, international study of mifepristone for symptomatic treatment of Cushing's syndrome caused by ectopic Adrenal Corticotrophin Hormone (ACTH) secretion. - HRA052015 in EASTreatment of Cushing's syndrome caused by ectopic Adrenal Corticotrophin Hormone (ACTH) secretion.MedDRA version: 14.0Level: PTClassification code 10011652Term: Cushing's syndromeSystem Organ Class: 10014698 - Endocrine disordersMedDRA version: 14.0Level: PTClassification code 10014146Term: Ectopic ACTH syndromeSystem Organ Class: 10014698 - Endocrine disorders

EUCTR2006-004679-36-DEaboratoire HRA Pharma35